2023
The role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiver
2021
Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection
Sharma L, Peng X, Qing H, Hilliard BK, Kim J, Swaminathan A, Tian J, Israni-Winger K, Zhang C, Habet V, Wang L, Gupta G, Tian X, Ma Y, Shin HJ, Kim SH, Kang MJ, Ishibe S, Young LH, Kotenko S, Compton S, Wilen CB, Wang A, Dela Cruz CS. Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection. Journal Of Virology 2021, 96: e01241-21. PMID: 34705554, PMCID: PMC8791255, DOI: 10.1128/jvi.01241-21.Peer-Reviewed Original ResearchConceptsType I interferonType III interferonsI interferonIII interferonsCoronavirus infectionInterferon deficiencyViral clearanceViral loadLung infectionType IHealthy young patientsImproved host survivalHost survivalRole of interferonMurine coronavirus infectionMajor health care threatViral burdenYounger patientsEarly diseaseIntranasal routeInterferon treatmentSublethal infectionEarly treatmentLethal infectionTissue injuryToward personalized treatment approaches for non-small-cell lung cancer
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine 2021, 27: 1345-1356. PMID: 34385702, DOI: 10.1038/s41591-021-01450-2.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCombination therapyMaintenance combination therapyRobust predictive biomarkersCancer-related deathPersonalized treatment approachesRational combination therapiesAdvanced NSCLCEarly diseasePredictive biomarkersClinical studiesCurrent treatmentCommon causePatient stratificationTreatment approachesTherapyNSCLCBreakthrough therapiesCancerClinical research areasImmunotherapyVast majorityCurrent understandingFuture roleThe Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
Marinov A, Wang H, Bastacky S, van Puijenbroek E, Schindler T, Speziale D, Perro M, Klein C, Nickerson K, Shlomchik M. The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis & Rheumatology 2021, 73: 826-836. PMID: 33277983, PMCID: PMC8084886, DOI: 10.1002/art.41608.Peer-Reviewed Original ResearchConceptsMRL/lpr miceB-cell depletionSystemic lupus erythematosusDiseased MRL/lpr miceLpr miceB cellsCell depletionEarly diseaseLupus-prone MRL/lpr micePathogenic B cellsAnti-CD20 antibodyClinical end pointsCD20 monoclonal antibodyMurine lupus modelsMultiple clinical end pointsAmelioration of diseaseAdvanced disease modelsAdvanced diseaseAutoantibody titersLupus nephritisLupus modelsLupus erythematosusInflammatory settingsSingle doseCD20 mAbs
2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal Of The National Cancer Institute 2019, 112: 46-54. PMID: 31037288, PMCID: PMC7850037, DOI: 10.1093/jnci/djz042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleGene ExpressionHumansLapatinibMiddle AgedMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm StagingPrognosisReceptor, ErbB-2Reproducibility of ResultsSurvival AnalysisTreatment OutcomeConceptsHER2-positive breast cancerProgression-free survivalOverall response rateHER2-positive diseasePathological complete responseOverall survivalBreast cancerEarly diseaseAdvanced HER2-positive diseaseLonger progression-free survivalHigher overall response rateDual HER2 blockadeLonger overall survivalHER2-positive tumorsHER2 blockadeNeoadjuvant lapatinibNeoadjuvant trastuzumabAdvanced diseaseComplete responsePrimary outcomeClinical trialsIntrinsic subtypesIdentifies tumorsAdvanced settingERBB2 mRNA
2016
Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice
Jung JJ, Razavian M, Kim HY, Ye Y, Golestani R, Toczek J, Zhang J, Sadeghi MM. Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice. Scientific Reports 2016, 6: 32659. PMID: 27619752, PMCID: PMC5020643, DOI: 10.1038/srep32659.Peer-Reviewed Original ResearchConceptsCalcific aortic valve diseaseAortic valve diseaseEffect of doxycyclineWestern dietCAVD progressionMatrix metalloproteinasesValve diseaseMicro-single photon emissionNonselective MMP inhibitorTherapeutic blood levelsLack of effectSingle photon emissionMatrix metalloproteinase inhibitorsGroups of animalsAortic stenosisMedical therapyHyperlipidemic miceEarly diseaseBlood levelsCommon causeTissue analysisMMP activationMMP inhibitionGelatinase activityDoxycycline
2015
Longitudinal assessment of lung function decline in the occupational setting
Redlich CA, Tarlo SM. Longitudinal assessment of lung function decline in the occupational setting. Current Opinion In Allergy And Clinical Immunology 2015, 15: 145-149. PMID: 25961387, DOI: 10.1097/aci.0000000000000153.Peer-Reviewed Original ResearchConceptsLongitudinal lung functionLung functionLongitudinal spirometryMedical surveillanceFlavorings-related lung diseaseHazardous work exposuresLung function declineOccupational respiratory diseasesRecent longitudinal studiesFunction declineEarly diseaseLung diseaseOccupational exposureRespiratory diseaseWork exposureSpirometryPreventive interventionsLongitudinal assessmentFurther evaluationOccupational settingsDiseaseLongitudinal studyCliniciansExposureRecent studies
2014
Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer
Neale RE, Clark PJ, Fawcett J, Fritschi L, Nagler BN, Risch HA, Walters RJ, Crawford WJ, Webb PM, Whiteman DC, Buchanan DD. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. Cancer Epidemiology 2014, 38: 576-582. PMID: 25201440, DOI: 10.1016/j.canep.2014.08.006.Peer-Reviewed Original ResearchConceptsPancreatic cancerWhite blood cell DNABlood cell DNAOdds ratioPresence of metastasesCancer-related deathPancreatic cancer casesHealthy unrelated controlsEarly diseaseCell DNALeading causeCancer casesWBC DNADNA repetitive elementsBlood collectionCancerConfidence intervalsUnrelated controlsMethylation scoreFurther studiesAssociationMarkersDeathPCR assaysQuantitative PCR assays
2011
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & Dementia 2011, 7: 532-539. PMID: 21889116, PMCID: PMC3299979, DOI: 10.1016/j.jalz.2011.05.2410.Peer-Reviewed Original Research
2010
Lyme Disease
Murray TS, Shapiro ED. Lyme Disease. Clinics In Laboratory Medicine 2010, 30: 311-328. PMID: 20513553, PMCID: PMC3652387, DOI: 10.1016/j.cll.2010.01.003.Peer-Reviewed Original ResearchConceptsLyme diseaseClinical presentation variesOnly nonspecific symptomsCranial nerve palsyMultiple erythema migransSigns of infectionCommon vector-borne diseaseNerve palsyDisseminated diseaseMost patientsNonspecific symptomsErythema migransSerologic testingAppropriate antimicrobialsEarly diseasePresentation variesLate diseaseObjective signsSpirochete Borrelia burgdorferiDiseaseBorrelia burgdorferiPatientsMigransSymptomsInfection
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trialsNeoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
Oh W. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urologic Oncology Seminars And Original Investigations 2003, 21: 229-234. PMID: 12810211, DOI: 10.1016/s1078-1439(03)00019-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAndrogen AntagonistsAndrogensAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkersChemotherapy, AdjuvantEstramustineFlutamideHumansLeuprolideMaleNeoadjuvant TherapyNeoplasms, Hormone-DependentPalliative CareProstatectomyProstatic NeoplasmsRandomized Controlled Trials as TopicRiskConceptsHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerClinical parameters of efficacyNeoadjuvant androgen deprivation therapyManagement of localized diseaseDefinitive local therapyDefinitive local treatmentHormone-refractory settingAndrogen deprivation therapyRisk of recurrenceMolecular targeted therapyParameters of efficacyAndrogen-dependent diseasesDeprivation therapyNeoadjuvant therapyRadical prostatectomyLocal therapySystemic therapyLocalized diseaseClinical parametersRandomized studyLocal treatmentEarly diseaseTherapy
2002
Diisocyanate asthma: clinical aspects and immunopathogenesis
Redlich CA, Karol MH. Diisocyanate asthma: clinical aspects and immunopathogenesis. International Immunopharmacology 2002, 2: 213-224. PMID: 11811926, DOI: 10.1016/s1567-5769(01)00174-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiisocyanate asthmaProduction of polyurethanesChemical reactivityBiological nucleophilesClinical aspectsChemical interactionReactive chemicalsRoute of exposureDiisocyanateSimple diagnostic testOccupational asthmaEarly diseaseRespiratory tractNonimmunological mechanismsWorkplace exposuresAsthmaUseful markerReactionDiagnostic testsDiseasePathogenesisImmunopathogenesisBiomoleculesNucleophilesExposure
1999
The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis
Combes B, Markin R, Wheeler D, Rubin R, West A, Mills A, Eigenbrodt E, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Carithers R. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999, 30: 602-605. PMID: 10462363, PMCID: PMC3935822, DOI: 10.1002/hep.510300315.Peer-Reviewed Original ResearchConceptsFlorid duct lesionsPrimary biliary cirrhosisBile duct destructionDuct lesionsUrsodeoxycholic acidDuct destructionBiliary cirrhosisPlacebo-controlled trialNeedle biopsy specimensUDCA patientsAdvanced diseasePlacebo medicationEarly diseaseBiopsy specimensPatientsLesionsBeneficial effectsPathology literaturePrevalenceCirrhosisPlaceboMedicationsDiseaseYearsHepatopathologistManagement of a Sabiá Virus-Infected Patient in a US Hospital
Armstrong L, Dembry L, Rainey P, Russi M, Khan A, Fischer S, Edberg S, Ksiazek T, Rollin P, Peters CJ. Management of a Sabiá Virus-Infected Patient in a US Hospital. Infection Control And Hospital Epidemiology 1999, 20: 176-182. PMID: 10100543, DOI: 10.1086/501607.Peer-Reviewed Original ResearchConceptsIsolation precautionsUS hospitalsViral hemorrhagic fever patientsUniversity-affiliated medical centerVirus-infected patientsLocal hospital settingLaboratory-acquired infectionsPatient care settingsEnhanced precautionsNosocomial transmissionEarly diseaseFever patientsVirus antibodiesHealthcare workersSecondary casesVirus infectionMedical CenterHospital settingSecondary infectionLocal hospitalPatientsHospital staffAerosol spreadSabiá virusClinical specimens
1994
IDENTIFICATION OF LYME DISEASE
Schoen R. IDENTIFICATION OF LYME DISEASE. Rheumatic Disease Clinics Of North America 1994, 20: 361-369. PMID: 8016416, DOI: 10.1016/s0889-857x(21)00053-3.Peer-Reviewed Original ResearchConceptsLate Lyme diseaseLyme diseaseSerologic testingMinority of patientsEarly Lyme diseaseChronic meningitisMost patientsRheumatic diseasesEarly diseaseChronic fatigueSuccessful treatmentDisease manifestationsHigh indexDiseasePatientsB. burgdorferiMost individualsAntibioticsTreatmentIndividualsOligoarthritisMeningitisRashSeroreactivityClinicians
1992
Serologic Diagnosis of Lyme Disease using Recombinant Outer Surface Proteins A and Band Flagellin
Fikrig E, Huguenel E, Berland R, Rahn D, Hardin J, Flavell R. Serologic Diagnosis of Lyme Disease using Recombinant Outer Surface Proteins A and Band Flagellin. The Journal Of Infectious Diseases 1992, 165: 1127-1132. PMID: 1583333, DOI: 10.1093/infdis/165.6.1127.Peer-Reviewed Original ResearchConceptsLyme diseaseRecombinant outer surface proteinRecombinant outer surface protein AB. burgdorferi antigensSurface protein AOuter surface protein AEarly diseaseLate diseaseSerologic diagnosisDiagnostic testingOuter surface proteinsImmunogenic regionPatientsDiseaseBorrelia burgdorferiELISAImmunoblotAntibodiesSurface proteinsFlagellinProtein AAntigenDiagnosis
1986
Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.
Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. Journal Of Clinical Investigation 1986, 78: 934-939. PMID: 3531237, PMCID: PMC423723, DOI: 10.1172/jci112683.Peer-Reviewed Original ResearchConceptsIgG responsesIgM responseEarly diseaseLyme diseaseImmunoglobulin M responseImmunoglobulin G responseBorrelia burgdorferiSpirochetal antigensG responsesIgG antibodiesProlonged illnessPatientsM responseIllnessDiseaseAntigenB. burgdorferiMonthsLimited responseIgMBurgdorferiSuch responsesResponseArthritisYears
1984
Antibody Response in Lyme Disease: Evaluation of Diagnostic Tests
Craft J, Grodzicki R, Steere A. Antibody Response in Lyme Disease: Evaluation of Diagnostic Tests. The Journal Of Infectious Diseases 1984, 149: 789-795. PMID: 6373966, DOI: 10.1093/infdis/149.5.789.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayAntibody responseLyme diseaseIgM antibodiesAntibody titersSpecific IgM antibody titersDiagnostic testsSpecific IgG antibody titersIgG antibody titersIgM antibody titersSerial serum samplesSpecific IgM antibodiesMonths of remissionCross-reactive antibodiesIxodes dammini spirocheteBetter diagnostic testsTiters of seraEarly diseaseControl subjectsAdsorption of serumPatientsSuch titersHigh titersDiseaseSerum samples
1983
The Spirochetal Etiology of Lyme Disease
Steere A, Grodzicki R, Kornblatt A, Craft J, Barbour A, Burgdorfer W, Schmid G, Johnson E, Malawista S. The Spirochetal Etiology of Lyme Disease. New England Journal Of Medicine 1983, 308: 733-740. PMID: 6828118, DOI: 10.1056/nejm198303313081301.Peer-Reviewed Original ResearchConceptsLyme diseaseAntibody titersIgM titersSpecific IgM antibody titersSpecific IgG antibody titersElevated IgM titersI. dammini spirocheteIgG antibody titersIgM antibody titersTiters of IgGOnset of diseaseInfectious mononucleosisControl patientsImmunologic featuresIgG titersEarly diseaseControl subjectsSpirochetal etiologySkin lesionsCerebrospinal fluidPatientsLate manifestationSixth weekDiseaseTiters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply